---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-017460"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:47:00.970006+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abeona closes sale of Rare Pediatric Disease PRV for $155M; cash at $225M

## Summary
- Closed sale of Rare Pediatric Disease Priority Review Voucher for $155M gross proceeds on June 27, 2025.
- Unrestricted cash, equivalents, and short-term investments totaled approximately $225M as of June 30, 2025.
- CFO expects over two years of operating capital without further capital infusion; profitability projected early 2026.
- First ZEVASKYN patient treatment anticipated in Q3 2025.

## SEC filing metadata
- accession: 0001641172-25-017460
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000164117225017460/0001641172-25-017460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000164117225017460/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-017460
- JSON: https://secwatch.observer/filing/0001641172-25-017460.json
- Plain text: https://secwatch.observer/filing/0001641172-25-017460.txt

## Key facts
- M&A Transactions
  ABEONA THERAPEUTICS INC. completed a disposition involving buyer for gross proceeds of $155 million (closed 2025-06-27).
  - Action: disposition
  - Counterparty: buyer
  - Consideration: gross proceeds of $155 million
  - Closing: 2025-06-27
  source text: terms of an asset purchase agreement dated May 9, 2025 (the “PRV Asset Purchase Agreement”). Pursuant to the PRV Asset Purchase Agreement, the Company received gross proceeds of $155 million from the buyer upon the closing of the Asset Sale. The foregoing description of the PRV Asset Purchase Agreement does not purport to be complete and is qualified in its entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000164117225017460/0001641172-25-017460-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.